BCRX Biocryst Pharmaceuticals Inc.

$BCRX Interesting uptick in volume. Will be interesting to see if there is a gradual continuation of this the remainder of Oct. We have Q3 ER coming up on or around Nov 2 and there are potentially two paths to an early 17725 November announcement: 1. Primary dataset only: Last patient completes Week 12 in October → database cleaned/analyzed → topline POC announced in November, while some patients remain in follow-up. 2. Nearly complete/full dataset: Last patient actually reaches Week 12 early enough in October that the eight-week follow-up concludes in late November → BioCryst analyzes efficacy plus follow-up and announces around late November/early December. The first scenario is especially plausible because this is an open-label study of only up to 12 patients, not a large blinded Phase 3 requiring an elaborate database lock. If anyone was considering taking up a position in the stock this week and next is going to be the best time to do it.

$BCRX I own some shares that will be 6 years old next month. I bought them for $7. Could’ve exited this years ago for a fleeting moment at $19. I know many here are in the same boat or worse. Where are we now? With seven new sacks of shit who will undoubtedly be paid handsomely in cash along with more shares at our expense. They’ve wasted so much here over the years and have diluted us into oblivion. That’s why the market has us where we’re at now.

$BCRX FWIW we are already up to 2.7 million block traded shares today. That is unusual before end of day. 🤔

$BCRX how can leadership possibly defend a sub-$8/share position and still say one of their primary goals is to create shareholder value. I fucking hate this stock. There is NO reason we should be in the $7's when generating the revenues that we do. I'm just so over this company. I feel like I'm being held prisoner waiting for any sort of respectable return on my investment.

$BCRX I wish I could say how shocked or confused I was that this is down 2% while the XBI is up 4, but is anyone who has been here for any length of time really either of those things? The shocking thing would probably be if it didn't end up sucking.

$BCRX If the Netherton POC data is exceptionally strong, it could encourage potential licensing partners to evaluate BCX17725 as something more than a single-indication orphan drug. That could increase partnering interest even before a second indication enters clinical trials. For example if the POC demonstrates remarkable restoration of skin-barrier function, I could envision Sanofi, Regeneron, Lilly or another dermatology-focused company becoming interested in licensing the molecule specifically to explore broader dermatologic applications such as atopic dermatitis.

$BCRX SI has not been this low as long as I can remember, and I've been in the 📩Stock for a long time The big drop a few weeks ago let some of the shorts off easily Keep adding Buyout sooner or later 🙏

$BCRX If revenues are growing and you have a drug in phase 3 and your stock is at 2 times sales management is truly a bunch of fuck ups.

$BCRX Weird, no messages showing on the 'Latest' section of the board. Glitchy Stocktwits strikes again.

$BCRX The last line of the "Why its trending" really points to a major issue IMO. "...question whether those prospects can restore confidence." The market does not believe in this company, and (more specifically) its management. I'm not sure what other reason there would be why no good news here is ever given any credence. It's treated more with a "they will screw that up" mentality and traded accordingly. Those of us who have been here long enough (God save us) keep waiting on the "correction" but the market clearly does not see what we see. Maybe solid Netherton or Navenibart data will finally sway them that management may not be perennial screw ups unworthy of trust. I can only hope.

$BCRX congrats to the longs that have endured the wait this run here should put you back at 12.40’s next jump you guys will see is back to 9.10 range and than get the break and run.

$BCRX Shorts have strong hold of this stock. Yearly Revenue will top $700 mill and we are stuck at $8. Shit makes no sense

$BCRX will the market allow this to run??we are at decision point. As structure shows high confluence based on rhythm. In picture 1 was pre launch structure run from 6.23-10.22. Now look at our current position in picture 2. In picture 1 we hit off the purple and than the green and ran. In picture 2 we did a double hit off of that purple line. Market is positioned to run. I will warn that I could see a downside test to 7.30 area if this fails to break out. As that looks like the most balanced trade we had where price was at an equilibrium showing support. In picture 3

$BCRX The market has zero confidence in management. Every time they make an announcement, they're punished for it. They need to stop ginning up ways to spend money. The ideas are shit. Sell the damn company.

$BCRX Pharvaris has yet to release granular safety data from CHAPTER-3. They haven’t announced when they will either. Most likely it’s nothing, but maybe they don’t want it out yet for some reason. Their SP dropped over 6% today, maybe I’m not the only one suspicious.

$BCRX Hopefully pediatric numbers released in November will be so impressive we’ll finally rise back above $12 by EOY. Shares bought under $12 will be well rewarded imo.

$BCRX Could double from here and it would be in the "normal"range for bios of 5-7x revs....

$BCRX At first, I was not crazy about this new committee. But I've stated to rationalize that it was a necessary move given our current BOD's track record. In fact - good for them realizing that this new external R&D model required a different approach and a separate group of personnel. No choice but to see what Menon, Jenkins, and this committee bring to the table.

$BCRX Like... does a single member of the mgmt team ever ask themselves why the market keeps punishing their ideas? "Gee.... I wonder why the share price plummets every time we open our mouths?" They're clueless.

$BCRX Now that they’ve disclosed the seven members of this new advisory board, they can start to finalize details of the buyout…